ZA200803370B - Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear - Google Patents

Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear

Info

Publication number
ZA200803370B
ZA200803370B ZA200803370A ZA200803370A ZA200803370B ZA 200803370 B ZA200803370 B ZA 200803370B ZA 200803370 A ZA200803370 A ZA 200803370A ZA 200803370 A ZA200803370 A ZA 200803370A ZA 200803370 B ZA200803370 B ZA 200803370B
Authority
ZA
South Africa
Prior art keywords
prevention
treatment
methods
drug delivery
nonionic surfactants
Prior art date
Application number
ZA200803370A
Other languages
English (en)
Inventor
Neil E Paulsen
Roland H Johnson
William R Campbell
Original Assignee
Piedmont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piedmont Pharmaceuticals Llc filed Critical Piedmont Pharmaceuticals Llc
Publication of ZA200803370B publication Critical patent/ZA200803370B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200803370A 2005-09-26 2006-08-25 Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear ZA200803370B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72053605P 2005-09-26 2005-09-26

Publications (1)

Publication Number Publication Date
ZA200803370B true ZA200803370B (en) 2009-09-30

Family

ID=37900209

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803370A ZA200803370B (en) 2005-09-26 2006-08-25 Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into middle ear

Country Status (11)

Country Link
US (1) US20080318918A1 (enExample)
EP (1) EP1931388A4 (enExample)
JP (1) JP2009509956A (enExample)
CN (1) CN101272807A (enExample)
AU (1) AU2006295248A1 (enExample)
BR (1) BRPI0616415A2 (enExample)
CA (1) CA2622002A1 (enExample)
EA (1) EA200800950A1 (enExample)
IL (1) IL190079A0 (enExample)
WO (1) WO2007037886A2 (enExample)
ZA (1) ZA200803370B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8271101B2 (en) * 2007-08-29 2012-09-18 Advanced Bionics Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead
RU2358743C1 (ru) * 2008-03-04 2009-06-20 Андрей Валериевич Давыдов Средство и способ лечения экссудативного среднего отита
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US11033624B2 (en) 2010-06-02 2021-06-15 Novaflux Inc. Medical item for prevention and treatment of ear infection
MD674Z (ro) * 2013-03-07 2014-04-30 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Metodă de tratament al otitei medii exudative la copii
US10166146B2 (en) 2013-03-08 2019-01-01 Mark Mitchnick Ear medication dispenser with sensor
CN105682742A (zh) 2013-08-27 2016-06-15 奥德纳米有限公司 小儿耳部病症的治疗
WO2015168642A1 (en) 2014-05-02 2015-11-05 Labib Mohamed E Drug-releasing device usable in mucosal body cavities
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549770A (en) * 1963-12-09 1970-12-22 Crown Zellerbach Corp Therapeutic administration of effective amounts of dimethyl sulfoxide to human and animal subjects
US5231112A (en) * 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
DE3936328A1 (de) * 1989-10-27 1991-05-02 Schering Ag Pharmazeutische praeparate
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
US6723714B2 (en) * 1999-07-06 2004-04-20 Blansett Pharmacal Co., Inc. Aqueous solvent for corticosteroids
WO2001015677A2 (en) * 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
HUP0303696A3 (en) * 2000-09-25 2005-05-30 Bayer Healthcare Llc Tarrytown Otic microbial combinations for treatment of animals with ruptured tympanic membrane
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2004052236A2 (en) * 2002-12-06 2004-06-24 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
LT1610613T (lt) * 2003-04-04 2017-03-27 Merial, Inc. Vietinio taikymo antihelmintinės veterinarinės kompozicijos
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US20080124385A1 (en) * 2004-09-03 2008-05-29 Piedmont Pharmaceuticals,Llc. Methods for Transmembrane Treatment and Prevention of Otitis Media
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use

Also Published As

Publication number Publication date
JP2009509956A (ja) 2009-03-12
WO2007037886A3 (en) 2007-10-25
CA2622002A1 (en) 2007-04-05
IL190079A0 (en) 2008-08-07
BRPI0616415A2 (pt) 2011-06-21
EA200800950A1 (ru) 2008-08-29
WO2007037886A2 (en) 2007-04-05
CN101272807A (zh) 2008-09-24
AU2006295248A1 (en) 2007-04-05
EP1931388A2 (en) 2008-06-18
US20080318918A1 (en) 2008-12-25
EP1931388A4 (en) 2010-12-15
WO2007037886B1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
IL190079A0 (en) Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear
IL190080A0 (en) Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate trasmembrane drug delivery into the middle ear
PL1881823T3 (pl) Kompozycje i sposoby leczenia chorób oczu
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
IL184735A0 (en) Pharmaceutical formulations and methods of use
GB2444688B (en) Motorized flosser and method of use
EP2293800A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES
ZA200710983B (en) Bacterial cellulose-containing formulations and method of producing effective bacterial cellulose-containing formulations
SI2182981T1 (sl) Postopki in sestavki za zdravljenje in diagnozo fibroze
EP2229052A4 (en) SEED TREATMENT FORMULATIONS AND METHODS OF USE
ZA200710858B (en) Diclofenac formulations and methods of use
EP2019646A4 (en) METHOD, DEVICE AND SYSTEM FOR THE RELEASE OF A THERAPEUTIC ACTIVE IN THE EYE
EP1945170A4 (en) METHOD AND APPARATUS FOR PROCESSING PREDOMINANT FREQUENCY ACOUPHENES
SI1884234T1 (sl) Profilaktično ali terapevtsko sredstvo za kornealno in konjunktivalno motnjo
EP1784164A4 (en) PROCESS FOR TRANSMEMBRANE TREATMENT AND PREVENTION OF OTITIS MEDIA
GB2445651B (en) Well treatment products and methods of using them
ZA200903653B (en) Methods for treatment of cochlear and vestibular disorders
EP2004387A4 (en) HEADPHONES FORMING DEVICE AND METHOD OF USE
PT1919290E (pt) Métodos e produtos para tratamento de doenças
IL191922A0 (en) Pharmaceutical formulations of oxcarbazepine and methods for its preparation
IL189146A0 (en) Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
EP1968481A4 (en) DEVICE AND DISTRIBUTION OF MEDICINALLY PURE OXYGEN
ZA200704725B (en) Product and method of treatment
ZA200806876B (en) Crystal form of besipirdine chlorhydrate, process preparation and use thereof
EP2066303A4 (en) METHOD AND SYSTEM FOR THE TREATMENT OF FOODSTUFFS